期刊
FUTURE ONCOLOGY
卷 14, 期 10, 页码 907-917出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0531
关键词
biomarkers; cancer vaccine; castration-resistant prostate cancer; immunotherapy; prostate cancer; sipuleucel-T
类别
资金
- NIH [P30 CA006973]
- Conquer Cancer Foundation/Bristol-Meyers Squibb Young Investigator Award
- Janssen
- Astellas
- Sanofi
- Dendreon
- Medivation
- ESSA
- AstraZeneca
- Clovis
- Merck
- Johnson Johnson
- Genentech
- Novartis
- Tokai
- Bristol Myers-Squibb
Sipuleucel-T, an autologous cellular immunotherapy manufactured from antigen-presenting cells primed to recognize prostatic acid phosphatase, was the first immunotherapy product approved by the US FDA. It was approved for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer after it was shown to provide a survival advantage. Additional studies have examined its use in other clinical settings and in combination with other approved and investigational immunotherapy agents. This review will discuss the pivotal trials leading to approval, will outline some of the biomarkers associated with its efficacy and will review some of the ongoing combination strategies. Maximizing the efficacy of sipuleucel-T through better patient selection or through combination approaches remains the challenge of the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据